As expected, the inhibitory effect of circSEMA4B on proliferation (Fig. 7f, g), migration, and invasion (Fig. 7h, i) was significantly weakened in BC cells treated with MK2206, indicating that circSEMA4B specifically targets PI3K/AKT pathway. The gene discussed is AKT1; the disease is breast cancer.